Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
B. Braun Melsungen AG, a leading name in the medical technology sector, is headquartered in Melsungen, Germany. Founded in 1839, the company has established itself as a key player in the development and manufacturing of precision medical instruments, with a focus on areas such as infusion therapy, pain management, and surgical instruments.
With a strong global presence, B. Braun operates in numerous regions, including Europe, Asia, and the Americas, providing innovative solutions that enhance patient care. The company is renowned for its commitment to quality and safety, offering a diverse range of products that include intravenous therapy systems and wound care solutions.
B. Braun's dedication to research and development has positioned it as a market leader, consistently achieving notable milestones in medical advancements and sustainability initiatives.
0 vs industry average
B. Braun Melsungen AG’s score of 32 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medical Device Manufacturing has below-average carbon intensity
The Medical Device Manufacturing industry has reduced its overall emissions by 32% since 2018
Scope 3 accounts for ••• of total emissions.
B. Braun Melsungen AG, headquartered in Germany and operating in the medical, precision, and optical instruments industry, reported its most recent emissions data for 2024. The company's total emissions for 2024 were approximately 98.7 million kg CO2e. This included about 832,000 kg CO2e from Scope 1 emissions, around 638,000 kg CO2e from Scope 2 emissions, and approximately 97.3 million kg CO2e from Scope 3 emissions. Key contributors to Scope 3 emissions in 2024 were the use of sold products (around 46.3 million kg CO2e), purchased goods and services (about 32.6 million kg CO2e), and upstream transportation and distribution (approximately 7.5 million kg CO2e). Emissions data for 2024, 2023, 2022, and 2021 are inherited from the parent company, B. Braun Melsungen AG.
Looking back, B. Braun Melsungen AG's Scope 1 and 2 emissions for 2023 were approximately 568 million kg CO2e, for 2022 they were about 612.3 million kg CO2e, and for 2021, they stood at around 653.4 million kg CO2e.
B. Braun Melsungen AG has set a near-term commitment to reduce its gross Greenhouse Gas Scope 1 and 2 carbon dioxide emissions by 50% by the end of 2030, using 2019 as a baseline. The company also aims to achieve Net Zero for all emissions by 2045.
Access structured emission data, company specific factors and auditable source documents
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more